- Home
- Products
Idhifa (Enasidenib)
Idhifa (Enasidenib)
- Medicine Name: Idhifa
- Generic Name: Enasidenib
- Dosage Form & Strength: Tablets – 50 mg and 100 mg
- Manufactured By: Celgene Corporation
Idhifa is an isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a confirmed IDH2 mutation.
Recommended Dosage:
- Treatment should begin only after confirming the presence of IDH2 mutations in the blood or bone marrow.
- The recommended dose is 100 mg orally once daily, with or without food.
- Tablets should be swallowed whole and should not be split or crushed.
- Treatment may continue until disease progression or intolerable side effects. Patients showing no progression or toxicity should continue therapy for a minimum of six months to assess response.
- If a dose is missed or vomited, take it as soon as possible on the same day and resume the regular dosing schedule the following day.
Monitoring: Regularly monitor blood counts and chemistries, especially during the first 3 months of therapy, to manage potential leukocytosis and tumor lysis syndrome.
Differentiation Syndrome: Idhifa may cause life-threatening differentiation syndrome. Initiate corticosteroids and close monitoring if symptoms develop. Hospitalization may be necessary.
Reproductive Risk: Idhifa may cause fetal harm. Both male and female patients of reproductive potential should use effective contraception during treatment and for at least 30 days post-therapy.
Breastfeeding: Women should avoid breastfeeding during treatment and for 30 days after the last dose due to potential risk to the infant.
Required Documents to Import Idhifa to India:
- Valid prescription from a licensed medical practitioner
- Diagnostic reports confirming IDH2 mutation
- Government-issued ID proof of the patient
Availability in India:
Idhifa is a prescription-only anticancer medication and can be imported to India legally for personal use under the Named Patient Import Program.
Global Rare Meds Provides:
- Access to verified global suppliers in the USA, Canada, Europe, and Australia
- Transparent pricing and end-to-end import guidance
- Delivery support to patients, doctors, and hospitals in cities such as Mumbai, Delhi, Chennai, Pune, Bengaluru, Ahmedabad, Kolkata, Hyderabad, and beyond
Order Confirmation:
Processing begins upon submission of a valid prescription and applicable import permit.
📧 info@globalraremeds.com
📞 +91-99675 15602 (Call/WhatsApp)
Global Rare Meds helps patients access genuine Idhifa (Enasidenib) through international supply channels. All medications are handled and delivered in accordance with regulatory guidelines from our licensed fulfillment center in Ambernath, Thane District, India.
We ensure:
- Quality-assured sourcing
- Licensed pharmacist verification
- Secure packaging and direct-to-doorstep delivery
Q: What is the generic name of Idhifa®?
A: Enasidenib
Q: Who manufactures Idhifa®?
A: Celgene Corporation
Q: Is Idhifa® FDA-approved?
A: Yes, Idhifa was approved by the U.S. FDA on August 1, 2017.
Q: What dosage forms are available for Idhifa®?
A: Tablets – 50 mg and 100 mg for oral use.
Q: What are the common side effects of Idhifa®?
A: Common side effects include increased bilirubin levels, nausea, decreased appetite, vomiting, and diarrhea.
Q: How should Idhifa® be stored?
A: Store at 20°C to 25°C. Keep tablets in the original bottle with desiccant and tightly closed to protect from moisture.
Q: What is the price of Idhifa® in India?
A: The price may vary based on availability and sourcing. For exact pricing, contact info@globalraremeds.com or call/WhatsApp +91-99675 15602.
Q: Can I legally buy Idhifa® online in India?
A: Yes. Global Rare Meds can facilitate the legal import of Idhifa with a valid prescription under Indian regulations.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
